ArticleHaematologica2023

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm.

Naseema Gangat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.